Key facts
- It has raised $71.0M; the latest was Later Stage VC ($21.8M) in Jan 2026.
- Notable investors include KB Investment, Korea Development Bank, Smilegate Investment, Shinhan Venture Investment, SJ Investment Partners — 28 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 28 names
- ·Watchlist + deal alerts for 1STBIO
- ·The full record, as it builds
Funding rounds
No funding rounds for 1STBIO are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About 1STBIO
Operator of a biotech company intended to develop a treatment for degenerative brain diseases. The company develops a pipeline of first-in-class investigational therapeutics with a clear mechanism for proper disease modification and good pharmacological properties, enabling healthcare professionals to research and develop therapies in neurodegenerative diseases, immuno-oncology, and rare diseases.
- Sector
- Healthcare
- HQ
- Yongin, South Korea
- Founded
- 2016
- Employees
- 29
- Website
- 1stbio.com/
- Ownership
- Privately Held (backing)
1STBIO doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in 1STBIO shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on 1STBIO in its N-PORT filings yet. We sweep new filings monthly.